Glucagon-like peptide-1 receptor agonists and risk of suicidality among patients with type 2 diabetes: active comparator, new user cohort study
In this large cohort study, the use of GLP-1 receptor agonists was not associated with an increased risk of suicidality compared with the use of DPP-4 inhibitors or SGLT-2 inhibitors in patients with type 2 diabetes.
Authors
- Oriana Hoi Yun Yu (ORCID: https://orcid.org/0000-0003-4877-557X)
- Samy Suissa (ORCID: https://orcid.org/0000-0002-1281-5296)
- Samantha B. Shapiro (ORCID: https://orcid.org/0000-0002-7957-508X)
- Laurent Azoulay (ORCID: https://orcid.org/0000-0001-5162-3556)
- Soham Rej (ORCID: https://orcid.org/0000-0002-3908-9124)
- Hui Yin
Institutions
- Jewish General Hospital (CA)
- McGill University (CA)
Publication Details
- Journal
- BMJ
- Published
- 2025-02-26
- DOI
- https://doi.org/10.1136/bmj-2024-080679
- Citations
- 30
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 38.85
Funders
- Canadian Institutes of Health Research